| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | ORKA Oruka Therapeutics, Inc. | Agarwal Arjun | Senior Vice President, Finance | Sell | 1,587 | $80.95 | $128,468.24 | -4.8% | - | - | |
| Jun 22, 2026 | KYMR Kymera Therapeutics, Inc. | Booth Bruce70 | Director | Sell | 31,798 | $103.75 | $3,299,037.16 | -0.4% | - | - | |
| Jun 22, 2026 | KYMR Kymera Therapeutics, Inc. | Booth Bruce70 | Director | Sell | 478,198 | $94.72 | $45,293,293.82 | -0.8% | - | - | |
| Jun 18, 2026 | CNXU Conexeu Sciences Inc. | Purcell Lynn Sebastian | Director, 10% Owner | Buy | 202,500 | $0.80 | $162,000.00 | +8.0% | - | - | |
| Jun 18, 2026 | MLTX Moonlake Immunotherapeutics | Bodenstedt Matthias66 | Chief Financial Officer | Sell | 17,876 | $19.67 | $351,576.16 | -0.8% | - | - | |
| Jun 18, 2026 | NBP Novabridge Biosciences | Dennis Phillip Andrew | Chief Medical Officer | Sell | 8,494 | $0.66 | $5,606.04 | -5.1% | - | - | |
| Jun 17, 2026 | ELVN Enliven Therapeutics, Inc. | Hohl Benjamin60 | Chief Financial Officer | Sell | 6,018 | $43.80 | $263,577.34 | -3.6% | - | - | |
| Jun 17, 2026 | ELVN Enliven Therapeutics, Inc. | Collins Helen Louise63 | Chief Medical Officer | Sell | 5,000 | $43.80 | $219,016.84 | -5.9% | - | - | |
| Jun 17, 2026 | ADTX Aditxt, Inc. | Drw Securities, LLC | 10% Owner | Sell | 126,772 | $0.01 | $1,001.50 | -100% | - | - | |
| Jun 17, 2026 | PTCT Ptc Therapeutics, Inc. | Boulding Mark Elliott55 | Exec. VP And CLO | Sell | 10,462 | $78.65 | $822,867.75 | -2.4% | - | - | |
| Jun 17, 2026 | MLYS Mineralys Therapeutics, Inc. | Karydas Daphne | Director | Sell | 3,000 | $25.00 | $75,000.00 | -32.6% | - | - | |
| Jun 17, 2026 | PTCT Ptc Therapeutics, Inc. | Utter Christine Marie58 | SVP, Chief Accounting Officer | Sell | 19,686 | $75.56 | $1,487,474.16 | -21.9% | - | - | |
| Jun 17, 2026 | MIRM Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, Global Controller | Sell | 2,594 | $101.95 | $264,458.30 | -30.8% | - | - | |
| Jun 17, 2026 | PVLA Palvella Therapeutics, Inc. | Goin Kathleen | Chief Operating Officer | Sell | 4,302 | $110.73 | $476,372.97 | -69.0% | - | - | |
| Jun 17, 2026 | CVKD Cadrenal Therapeutics, Inc. | Pham Quang X49 | Chairman, CEO And Interim CFO | Sell | 4,126 | $3.18 | $13,110.42 | -1.6% | - | - | |
| Jun 17, 2026 | MLTX Moonlake Immunotherapeutics | Reich Kristian78 | Chief Scientific Officer | Sell | 150,000 | $19.01 | $2,851,000.00 | -1.7% | - | - | |
| Jun 17, 2026 | MLYS Mineralys Therapeutics, Inc. | Rodman David Malcom56 | Chief Medical Officer | Sell | 14,474 | $24.19 | $350,086.83 | -11.2% | - | - | |
| Jun 17, 2026 | ARQT Arcutis Biotherapeutics, Inc. | Welgus Howard G.60 | Director | Sell | 4,731 | $24.58 | $116,280.94 | -5.9% | - | - | |
| Jun 17, 2026 | OTLC Oncotelic Therapeutics, Inc. | Trieu Vuong | Chairman And CEO | Buy | 335,759 | $0.04 | $15,013.25 | +0.2% | - | - | |
| Jun 17, 2026 | ABOS Acumen Pharmaceuticals, Inc. | Porter Derrell | Director | Sell | 32,300 | $2.33 | $75,239.50 | -21.3% | - | - | |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | Kerr Douglas59 | Chief Medical Officer | Sell | 887 | $18.33 | $16,258.71 | -0.5% | - | - | |
| Jun 16, 2026 | DYN Dyne Therapeutics, Inc. | Cox John | CEO &President | Sell | 2,683 | $18.33 | $49,179.39 | -0.7% | - | - | |
| Jun 16, 2026 | UPB Upstream Bio, Inc. | Deykin Aaron | Chief Medical Officer | Sell | 895 | $6.10 | $5,459.50 | -2.6% | - | - | |
| Jun 16, 2026 | KRRO Korro Bio, Inc. | Cerio Jeffrey | General Counsel | Sell | 6,609 | $10.83 | $71,575.47 | -15.8% | - | - | |
| Jun 16, 2026 | KRRO Korro Bio, Inc. | Chappell Todd | Chief Operating Officer | Sell | 3,168 | $10.83 | $34,309.44 | -15.7% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.